Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Pemvidutide, an investigational dual-pathway therapy, demonstrates sustained metabolic improvements across liver function, lipid profiles, and cardiovascular risk markers in a 48-week Phase 2b trial. The data suggest a mechanistic advantage over single-pathway GLP-1 agents by addressing the interconnected metabolic dysfunction underlying fatty liver disease and cardiovascular risk.
LET-607, a transcription factor in C. elegans, enforces a trade-off between two protein-quality control systems—suppressing cytosolic stress response while promoting endoplasmic reticulum stress response. Removing LET-607 rebalances this allocation, enhancing cytosolic protein quality control and extending lifespan, suggesting that developmental optimization sacrifices longevity potential.
Haut.AI has launched an AI-powered platform that analyzes skin across the entire body—not just the face—to provide quantitative measurements and personalized product recommendations. The technology was trained on over 100,000 skin images across all skin types and validated for clinical accuracy, addressing a market gap where 80% of consumers report pressure to maintain healthy-looking skin.
AI care robots demonstrated measurable reductions in loneliness and depressive symptoms among isolated older adults in South Korea, with effectiveness sustained over a 12-week intervention period. The mechanism appears to involve both direct companionship and the initiation of human social contact through robot-facilitated engagement.
Annovis Bio has enrolled 850 patients with early Alzheimer's disease in a Phase 3 trial of Buntanetap, a daily oral therapeutic targeting pTau217 pathology. The dual-endpoint design will assess both symptomatic improvement at six months and disease-modifying effects at 18 months, with regulatory submissions anticipated in 2027-2028.
Reproductive behaviors interact with genetic susceptibility to modulate aging trajectories, with certain lifestyle patterns amplifying or buffering age-acceleration risk in genetically predisposed individuals. This research identifies a modifiable behavioral layer that operates independently of genetic burden, suggesting that aging rate is not fixed by inheritance alone.
Disrupted calcium ion homeostasis accelerates aging through a pathway involving the protein S100A6 and impaired DNA repair. Restoring calcium balance with mianserin, an existing antidepressant, extended median lifespan by approximately 30% in progeroid mice and improved multiple tissue functions.
BioAge has initiated Phase 2 testing of BGE-102, an NLRP3 inflammasome inhibitor, to assess whether reducing systemic inflammation improves cardiovascular outcomes in adults at elevated risk. The trial represents a shift in drug discovery methodology—identifying therapeutic targets through analysis of successful aging biology rather than disease pathology—potentially targeting a shared mechanism underlying multiple age-related conditions.
Insilico Medicine's rentosertib, an AI-designed TNIK inhibitor discovered through aging-biology-informed target identification, has advanced to Phase III trials for idiopathic pulmonary fibrosis. The program demonstrates that computational drug discovery combined with geroscience principles can identify therapeutically relevant targets overlooked by conventional approaches.
Alterity Therapeutics has secured FDA alignment on a registrational pathway for ATH434, a candidate treatment for multiple system atrophy, with agreement on primary endpoints, dosing, and trial design based on Phase 2 efficacy data. This regulatory clarity positions the program for pivotal Phase 3 initiation by late 2026, addressing a neurodegenerative disease with no approved disease-modifying therapies.
Integration of at-home EEG sleep monitoring into decentralized clinical trials enables objective measurement of sleep architecture with 88-96% agreement to laboratory polysomnography. This addresses a critical measurement gap in CNS studies where sleep quality directly influences neurological outcomes and therapeutic response.
Rural older adults in Korea engage in significantly less moderate-intensity physical activity than urban counterparts, driven by differences in healthcare access, transportation, and social infrastructure rather than health status alone. This disparity represents a modifiable risk factor for accelerated aging and reduced healthspan in underserved populations.